{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"17.7","value":"6.4"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"8.9","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Progression-free Survival is defined as the duration alive from study entry until progression is documented, or death; whichever comes sooner. Progressive disease is defined as at least a 5 mm absolute increase and a 20% relative increase in the sum of measurable target lesions' longest dimensions relative to the smallest sum at baseline or on study or the appearance of new lesions or unequivocal progression of existing non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus 10 mg daily plus letrozole 2.5 mg PO daily in a 28 day cycle.","id":"OG000","title":"Everolimus and Letrozole"},{"description":"Tamoxifen 20 mg PO bid days 1-28 plus medroxyprogesterone acetate 200 mg PO days 8-14 and 22-28 repeating in a 28 day cycle.","id":"OG001","title":"Tamoxifen and Medroxyprogesterone Acetate"}],"paramType":"MEDIAN","populationDescription":"Eligible Patients","reportingStatus":"POSTED","timeFrame":"Tumor measurements were done at 8 and 16 weeks after initiating treatment and then every 12 weeks and compared with baseline measurements prior to treatment. Measurements are continued until disease progression is documented or death.","title":"Median Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}